Cutaneous anaplastic large cell lymphoma in a multiple sclerosis patient receiving Fingolimod

Previous reports of cutaneous neoplastic lesions secondary to Fingolimod treatment among multiple sclerosis patients. Reporting a case of cutaneous large cell lymphoma in a multiple sclerosis patient during Fingolimod treatment. Case study. Our patient developed CD30+ cutaneous large cell lymphoma two years after initiation of Fingolimod treatment and her symptoms regressed following the cessation of treatment. This report indicates that cutaneous lymphoid neoplasms should be considered a possible side effect among patients receiving Fingolimod. •A case of cutaneous anaplastic lymphoma during treatment by Fingolimod is presented.•The primary clinical presentation and progression of the lesion is reported.•The possible causal relation between Fingolimod and lesion is explained.